2017
DOI: 10.1016/j.neuropharm.2017.03.035
|View full text |Cite
|
Sign up to set email alerts
|

Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

5
63
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 19 publications
(68 citation statements)
references
References 73 publications
5
63
0
Order By: Relevance
“…We previously reported that Er-NPCs release erythropoietin ( Marfia et al, 2011 ), and their intrastriatal injection promoted recovery of function in a model of Parkinson’s disease through erythropoietin release ( Carelli et al, 2016 ; Carelli et al, 2017 ). After i.v.…”
Section: Discussionmentioning
confidence: 99%
“…We previously reported that Er-NPCs release erythropoietin ( Marfia et al, 2011 ), and their intrastriatal injection promoted recovery of function in a model of Parkinson’s disease through erythropoietin release ( Carelli et al, 2016 ; Carelli et al, 2017 ). After i.v.…”
Section: Discussionmentioning
confidence: 99%
“…Neural stem cells (NSCs) are multipotent stem cells present in the central nervous system (CNS) with self-renewing capabilities and the ability to generate all the main cellular phenotypes present in the nervous system, including neurons, astrocytes and oligodendrocytes [1]. NSCs were first observed as resident progenitors in the sub-ventricular zone (SVZ) and dentate gyrus of the mouse brain [2], and have later found a strong use in regenerative medicine [3][4][5][6][7][8][9]. In that context, NSCs are described to act both by releasing anti-inflammatory soluble factors and by differentiating into cellular components of the CNS [4][5][6][7][8][9][10][11][12].…”
Section: Introductionmentioning
confidence: 99%
“…NSCs were first observed as resident progenitors in the sub-ventricular zone (SVZ) and dentate gyrus of the mouse brain [2], and have later found a strong use in regenerative medicine [3][4][5][6][7][8][9]. In that context, NSCs are described to act both by releasing anti-inflammatory soluble factors and by differentiating into cellular components of the CNS [4][5][6][7][8][9][10][11][12]. Many progresses have been made in understanding the factors that regulate adult NSCs' specification, proliferation and differentiation, but much remains to be understood, especially the potential involvement of RNA-binding proteins (RBPs) and long non-coding RNAs (lncRNAs) in these processes [13].…”
Section: Introductionmentioning
confidence: 99%
“…EPO has protective and treating effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced neurotoxicity in this mouse model of Parkinson's Disease via increasing nitric oxide production [5,6]. In addition, Carelli et al [47] study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced Parkinsonism in mice. Unilateral stereotaxic injection of erythropoietin-releasing neural precursor cells can rescue degenerating striatal DA neurons and promote behavioral recovery [47].…”
Section: Introductionmentioning
confidence: 92%
“…In addition, Carelli et al [47] study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced Parkinsonism in mice. Unilateral stereotaxic injection of erythropoietin-releasing neural precursor cells can rescue degenerating striatal DA neurons and promote behavioral recovery [47]. Recently, two studies in humans have investigated safety and efficacy of EPO treatment of PD patients.…”
Section: Introductionmentioning
confidence: 98%